BioStructures, LLC has announced the first application of Prohesion, its patented surgical wound technology that is an activated type I collagen wound filler. With Prohesion, type I collagen fragments that have been sheared to a powder format.
BioStructures: First Application of Prohesion
1 min read Premium comments
Secondary
BioStructures CEO Russell Cook stated in the June 2, 2015 news release, “We are very pleased to offer another unique and innovative product under the BioStructures umbrella. Utilizing our expertise in collagen, we are able to offer products that not only assist in better patient care, but will benefit the hospital by reducing complications with surgical wounds. Prohesion provides yet another technology platform expanding on our Bioactive, Collagen, Synthetic, DBM and Allograft suite of products.”
Asked about an interesting point during the development phase, Cook told OTW, “We were able to identify a need of spine surgeons for which a comprehensive solution is not currently available. The need for a solution that was identified was complications associated with surgical wounds. BioStructures’ Prohesion allows the surgeon to apply hydrolyzed active collagen fragments to the surgical wound which benefits all phases of wound care including inflammation, proliferation, maturation, infection, granulation and remodeling.”
“It is our hope that Prohesion will eventually become the standard of care for hospital facilities in the management of surgical wounds.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.